[1]
|
赖李群, 徐凯, 吴燕群. 乙型肝炎的流行现状和传播途径及其防控策略[J]. 中国全科医学, 2023, 26(27): 3468.
|
[2]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华临床感染病杂志, 2022(6): 401-427.
|
[3]
|
Tricot, T., Thibaut, H.J., Abbasi, K., Boon, R., Helsen, N., Kumar, M., et al. (2022) Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. Biomedicines, 10, Article No. 268. https://doi.org/10.3390/biomedicines10020268
|
[4]
|
Marcellin, P., Wong, D.K., Sievert, W., Buggisch, P., Petersen, J., Flisiak, R., et al. (2019) Ten‐Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Virus Infection. Liver International, 39, 1868-1875. https://doi.org/10.1111/liv.14155
|
[5]
|
WHO (2010) International Statistical Classification of Diseases and Related Health Problems (ICD).
|
[6]
|
马蓉霞, 张文杰, 杨晓娟, 等. 不同病因肝硬化患者临床特征及其预后影响因素分析[J]. 现代生物医学进展, 2023, 23(19): 3683-3689.
|
[7]
|
Wang, L., Xu, X., Zhang, M., Hu, C., Zhang, X., Li, C., et al. (2023) Prevalence of Chronic Kidney Disease in China: Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine, 183, 298-310. https://doi.org/10.1001/jamainternmed.2022.6817
|
[8]
|
Kupin, W.L. (2016) Viral-Associated GN: Hepatitis B and Other Viral Infections. Clinical Journal of the American Society of Nephrology, 12, 1529-1533. https://doi.org/10.2215/cjn.09180816
|
[9]
|
Chen, J., Hubbard, A., Bagley, L., Shiau, R., Wong, R.J. and Chitnis, A.S. (2021) Prevalence of Latent Tuberculosis Infection among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 67, 2646-2654. https://doi.org/10.1007/s10620-021-07056-5
|
[10]
|
杨旭洁, 焦琳, 白浩, 等. 肺结核患者发生乙型肝炎病毒共感染遗传易感性的全基因组关联分析[J]. 华西医学, 2019, 34(8): 885-889.
|
[11]
|
Bazinet, M., Pântea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. (2020) Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology, 158, 2180-2194. https://doi.org/10.1053/j.gastro.2020.02.058
|
[12]
|
Zhang, M., Zhang, Z., Imamura, M., Osawa, M., Teraoka, Y., Piotrowski, J., et al. (2021) Infection Courses, Virological Features and IFN-α Responses of HBV Genotypes in Cell Culture and Animal Models. Journal of Hepatology, 75, 1335-1345. https://doi.org/10.1016/j.jhep.2021.07.030
|
[13]
|
Liu, Y., Zheng, Y., Lin, X., Cao, Z., Lu, J., Ma, L., et al. (2023) Analysis of Clinical Characteristics of Thyroid Disorders in Patients with Chronic Hepatitis B Treated with Pegylated-Interferon Alpha. BMC Endocrine Disorders, 23, Article No. 115. https://doi.org/10.1186/s12902-023-01371-w
|
[14]
|
Ma, Z., Qin, Y., Jia, Y., Xie, Y., Qi, X., Guo, Y., et al. (2022) Thyroid Dysfunction Incidence and Risk Factors in Chinese Chronic Hepatitis B Patients Treated with Pegylated Interferon Alpha: A Long‐Term Follow‐Up Study. Journal of Viral Hepatitis, 29, 412-419. https://doi.org/10.1111/jvh.13667
|
[15]
|
Kozielewicz, D., Zaleśna, A. and Dybowska, D. (2014) Can Pegylated Interferon α 2a Cause Development of Thyroid Disorders in Patients with Chronic Hepatitis B? Expert Opinion on Drug Safety, 13, 1009-1014. https://doi.org/10.1517/14740338.2014.921156
|
[16]
|
Liu, L., Li, P., Mi, Y., Liu, Y., Liu, Y. and Zhang, P. (2019) Thyroid-Stimulating Hormone Is Associated with Nonalcoholic Steatohepatitis in Patients with Chronic Hepatitis B. Medicine, 98, e17945. https://doi.org/10.1097/md.0000000000017945
|
[17]
|
Chung, J.W., Choi, H.Y., Ki, M., Jang, E.S. and Jeong, S. (2021) Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study. Gut and Liver, 15, 295-306. https://doi.org/10.5009/gnl19387
|